Demographics
| | |
Age – yrs
|
34 ± 13.2
|
63 ± 11.3
|
Female gender
|
232 (61.9)
|
535 (55)
|
Caucasian
|
246 (65.6)
|
595 (61.1)
|
BMI – kg/m2
|
24 ± 3.7
|
29 ± 5.3
|
25-30
|
16 (4.3)
|
255 (26.5)
|
30-35
|
4 (1.1)
|
119 (12.4)
|
>35
|
12 (3.2)
|
3 (0.3)
|
Waist circumference, male, cm
|
86 ± 11.4
|
102 ± 12.8
|
Waist circumference, female, cm
|
80 ± 11.9
|
96 ± 13.8
|
Socioeconomic profile
| | |
University level or higher
|
201 (53.7)
|
321 (33.5)
|
Private health insurance
|
310 (82.7)
|
833 (85.1)
|
Full/part time employment
|
263 (70.7)
|
381 (38.9)
|
Sick leave if employed*
|
26 (6.9)
|
21 (2.1)
|
Unemployment related to disability
|
67 (17.8)
|
364 (37)
|
Laboratorial measurements
| | |
Fasting plasma glucose – mg/dL
|
151 ± 81.7
|
143 ± 57.2
|
Glycated hemoglobin – %
|
8.4 ± 1.9
|
7.5 ± 1.6
|
Total cholesterol – mg/dL
|
179 ± 45.2
|
181 ± 41.6
|
LDL-cholesterol – mg/dL
|
102 ± 33.5
|
102 ± 39.2
|
HDL-cholesterol – mg/dL
|
58 ± 41.2
|
48 ± 22.5
|
Triglycerides – mg/dL
|
103 ±74.9
|
157 ± 105
|
Time since diagnosis – yrs
|
16 ± 10.8
|
11 ± 8.7
|
Medications
|
Use of glucose-lowering drug
|
43 (11.5)
|
827 (84.1)
|
Metformin
|
31 (8.3)
|
270 (27.5)
|
Sulphonylureas
|
1 (0.3)
|
60 (6.1)
|
Metformin + sulphonylureas
|
1 (0.3)
|
309 (31.4)
|
Others
|
10 (2.7)
|
188 (19.1)
|
Number of glucose-lowering drugs
| | |
1
|
37 (9.9)
|
379 (38.6)
|
2
|
6 (1.6)
|
344 (35)
|
>2
|
0 (0)
|
104 (10.6)
|
Insulin
|
375 (100)
|
343 (34.8)
|
ACEi/ARB
|
85 (22.7)
|
582 (59.2)
|
Antiplatelet agent
|
66 (17.6)
|
465 (47.3)
|
Statins
|
68 (18.1)
|
478 (48.6)
|
Hospital admissions*
|
30 (9.1)
|
40 (4.5)
|
Diabetes complications
| | |
Retinopathy
|
106 (28.3)
|
204 (20.7)
|
Neuropathy
|
65 (17.3)
|
200 (20.3)
|
Proteinuria¶
|
89 (23.7)
|
190 (19.3)
|
Dialysis
|
16 (4.3)
|
43 (4.3)
|
Acute coronary syndrome
|
7 (1.8)
|
102 (10.4)
|
Heart failure
|
5 (1.3)
|
50 (5)
|
Stroke
|
4 (1)
|
42 (4.2)
|
Peripheral vascular disease
|
14 (3.7)
|
134 (13.6)
|